Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +8 vs. previous quarter
- 53
- 13F valueReported value at the end of Q2 2026
- $32.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ARMP, Q2 2026
No superinvestor reported holding ARMP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Armata Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 12, 2023 (view filing)9:21 PM ET | Jan 10 | 2 days | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +19.7M | – | – | – | DerivativePrice outlier |
| Apr 1, 2022 (view filing)4:52 PM ET | Mar 31 | 1 day | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +5.39M | $5.00 | +$26.9M | +49.0%16.4M after | |
| Apr 1, 2022 (view filing)4:52 PM ET | Mar 31 | 1 day | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +2.69M | $0.00 | $0 | –2.69M after | Derivative |
| Feb 11, 2022 (view filing)6:56 PM ET | Feb 9 | 2 days | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +3.61M | $5.00 | +$18.1M | +49.1%11.0M after | |
| Feb 11, 2022 (view filing)6:56 PM ET | Feb 9 | 2 days | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +1.81M | $5.00 | +$9.04M | –1.81M after | Derivative |
| Nov 1, 2021 (view filing)2:20 PM ET | Oct 29 | 3 days | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +1.21M | $3.30 | +$4.00M | +19.7%7.37M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Armata Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Madison Asset Management, LLC | 2,107,175 | $13.7M | 0.16% | −5000.0% | Reduced |
| BlackRock, Inc. | 559,986 | $3.63M | 0.00% | +494,936+760.9% | Added |
| Vanguard Capital Management LLC | 487,968 | $3.16M | 0.00% | +121,940+33.3% | Added |
| Millennium Management LLC | 470,500 | $3.05M | 0.00% | +212,508+82.4% | Added |
| Geode Capital Management, LLC | 270,550 | $1.75M | 0.00% | +155,995+136.2% | Added |
| Dauntless Investment Group, LLC | 203,891 | $1.32M | 2.29% | +113,311+125.1% | Added |
| State Street Corp | 129,600 | $839.8K | 0.00% | +78,800+155.1% | Added |
| Northern Trust Corp | 89,791 | $581.8K | 0.00% | +65,145+264.3% | Added |
| Vanguard Portfolio Management LLC | 81,354 | $527.2K | 0.00% | +81,354 | New |
| Edgewood Management LLC | 80,000 | $518.4K | 0.01% | −20,000−20.0% | Reduced |